Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Drug Induced Renal Injury Consortium
NCT02159209 · View on ClinicalTrials.gov ↗
Study Summary
Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Patients who are exposed to these important medications and develop problems with their kidneys may have some genetic risk. The purpose of this study is to determine the genetic risk factors for drug induced kidney injury. A better understanding of the role of genetics for the development of kidney injury from medications will allow us to better select medications, improve effectiveness of treatment and minimize harm.
Conditions Studied
Study Locations (18)
Other
- Universidad del Valle, Cochabamba — Cochabamba
- Universidad de Los Andes — Santiago
- Postgraduate Institute of Research, Chandigarh — Chandigarh
- Royal Free Hospital — London
- Guy's & St Thomas's Hospital — London
- University of Nottingham — Nottingham
California
- University of California, San Diego — San Diego
- Rady Children's Hospital — San Diego
New York
- St. Peter's Hospital — Albany
- Jacobi Medical Center — New York
Alabama
- University of Alabama, Birmingham — Birmingham
Colorado
- University of Colorado — Aurora
Michigan
- University of Michigan — Ann Arbor
Ohio
- Cincinnati Children's Hospital — Cincinnati
Quebec
- Hopital Sacre Coeur & Universite de Montreal — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159209
The ClinicalTrials.gov registry entry for NCT02159209 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 634 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ravindra Mehta, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02159209 reports 18 study locations spanning 11 distinct geographic areas — top geographies include Other, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02159209 about?
NCT02159209 is a clinical study titled "The Drug Induced Renal Injury Consortium". Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Pat...
What is the current status of trial NCT02159209?
This trial is currently completed. The enrollment target is 634 participants. The study started on 2013-02. Estimated completion is 2015-12.
What conditions does trial NCT02159209 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Kidney Disease, Kidney Failure, Acute Kidney Failure, Adverse Drug Reaction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02159209?
This trial is sponsored by Ravindra Mehta, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02159209 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.